Synaptogenix Announces Corporate Update Conference Call
Synaptogenix, Inc. (Nasdaq: SNPX) announced a corporate update conference call scheduled for July 26, 2022, at 4:30 PM ET. The call will be led by CEO Dr. Alan Tuchman and President Dr. Daniel Alkon, with a live Q&A session following their remarks. The call will discuss updates on the company's development of regenerative therapeutics for neurodegenerative disorders, particularly focusing on Bryostatin-1 for Multiple Sclerosis and Alzheimer's disease. Forward-looking statements regarding clinical trials are included, highlighting potential risks and uncertainties.
- Announcement of a corporate update conference call indicates active communication with investors.
- Focus on developing Bryostatin-1 for Multiple Sclerosis and Alzheimer's shows commitment to addressing significant health issues.
- Forward-looking statements underline risks related to clinical trials, including potential safety and efficacy issues.
- There is uncertainty regarding the ability to secure financing for ongoing drug development.
NEW YORK, July 21, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that it will hold a corporate update conference call for investors. The call will take place on Tuesday, July 26th at 4:30pm ET and will be hosted by the Company's Chief Executive Officer, Dr. Alan Tuchman, and its President and Chief Science Officer, Dr. Daniel Alkon. Drs. Tuchman and Alkon will also take live Q&A following their prepared remarks.
The U.S. toll free dial-in for the conference call is (877) 407-8293, and the international dial-in number is 1-(201) 689-8349.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the anticipated initiation of a clinical trial to treat Multiple Sclerosis with bryostatin and continued development of use of Bryostatin-1 for Alzheimer's disease, Fragile X and other cognitive diseases. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. There can be no assurance that the clinical program for Bryostatin-1 will be successful in demonstrating safety and/or efficacy, that we will not encounter problems or delays in clinical development, or that Bryostatin-1 will ever receive regulatory approval or be successfully commercialized. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Additional factors that may influence or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company's patent portfolio, the Company's inability to expand its business, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company's raw materials, existing or increased competition, stock volatility and illiquidity, and the Company's failure to implement its business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange Commission. The Company does not undertake to update these forward-looking statements.
Contact information:
Investors and Media
800-811-5591
ir@synaptogen.com
Robert Weinstein
Chief Financial Officer
Synaptogenix, Inc.
rweinstein@synaptogen.com
View original content:https://www.prnewswire.com/news-releases/synaptogenix-announces-corporate-update-conference-call-301591017.html
SOURCE Synaptogenix, Inc.
FAQ
What is the date and time of the Synaptogenix SNPX conference call?
Who will host the Synaptogenix conference call?
What topics will be covered in the SNPX conference call?
Are there risks associated with Synaptogenix's clinical trials?
